Evommune to Present EVO301 Phase 2a Data at EADV 2026
PALO ALTO, Calif. and NEW YORK — September 23, 2026 Evommune, Inc. announced that Phase 2a data for EVO301...
Biotech
Advertisement
Upstream Bio Advances Verekitug Toward Phase 3 in Asthma
WALTHAM, Mass. — September 8, 2026 Upstream Bio, Inc. presented results from the Phase 2 VALIANT trial of verekitug...
Alumis Advances Envudeucitinib Toward Phase 3 in SLE
SAN FRANCISCO, Sept. 1, 2026 Alumis Inc. announced topline results from its Phase 2b LUMUS trial of envudeucitinib in...
Arch Biopartners Gains U.S. IRB Approval for LSALT Phase II
TORONTO, Canada, August 31, 2026 Arch Biopartners Inc. announced that it has received central Institutional Review Board (IRB) approval...
Slate Medicines Doses First Participant in SLTE-1009 Study
RALEIGH, N.C. – August 27, 2026 Slate Medicines Inc. announced that the first participant has been dosed in its...
Advertisements
Alzamend Neuro Advances Lithium Imaging Research
ATLANTA, August 18, 2026 Alzamend Neuro, Inc. announced that pharmacokinetic imaging data from its Phase 1/2A clinical trial of...
FibroBiologics Advances Cartilage Repair With Cell Therapy
HOUSTON, August 18, 2026 FibroBiologics, Inc., a clinical-stage biotechnology company developing therapies based on fibroblast cells and fibroblast-derived materials,...
Cumulus NeuLogiq Advances At-Home ALS and FTD Research
DUBLIN, Ireland, August 18, 2026 Cumulus Neuroscience has announced publication of final results from its CNS-102 study in Scientific...
BillionToOne Strengthens Evidence for Prenatal cfDNA Screening
MENLO PARK, Calif., August 18, 2026 BillionToOne, Inc., a molecular diagnostics company developing quantitative genetic testing technologies, has announced...
Curavit Expands Global Clinical Trial Capabilities
BOSTON, August 18, 2026 Curavit Clinical Research, a next-generation clinical research organization (CRO) and Remote Clinical Site, announced the...
Advertisement
